(R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole,
(R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide,
3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide,
eletriptan,
eletriptan hydrobromide,
Relpax,
UK 166,044,
UK 166044,
UK-116,044-04,
UK-116044-04,
UK-166,044,
UK-166044,
Eletriptan hydrobromide,
177834-92-3,
Eletriptan HBr,
UNII-M41W832TA3,
(R)-3-((1-Methylpyrrolidin-2-yl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide,
eletriptan monohydrobromide,
UK 116044-04,
CHEBI:61176,
M41W832TA3,
(R)-3-((1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide,
Eletriptan Hydrobromide [USAN],
3-[[(2R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole Hydrobromide,
5-[2-(phenylsulfonyl)ethyl]-3-[(2R)-pyrrolidin-2-ylmethyl]-1H-indole hydrobromide,
Relert,
Relpax (TN),
eletriptan-hydrobromide,
AC1LCVBD,
C22H26N2O2S.HBr,
RelpaxAlso see: E505000,
SCHEMBL317370,
CHEMBL1201003,
UTINOWOSWSPFLJ-FSRHSHDFSA-N,
1H-Indole, 3-(((2R)-1-methyl-2-pyrrolidinyl))methyl)-5-(2-(phenylsulfonyl)ethyl)-, monohydrobromide,
3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole, monohydrobromide,
HY-A0010,
Eletriptan hydrobromide (JAN/USAN),
Tox21_500408,
MFCD08141806,
s3180,
AKOS024262728,
AC-3398,
API0008562,
BCP9000640,
CCG-221712,
CS-0379,
RL02268,
Eletriptan hydrobromide|177834-92-3,
NCGC00261093-01,
Eletriptan hydrobromide, >=98% (HPLC),
SC-26797,
ST24035397,
SW220149-1,
UK-11604404,
D01973,
UK-116,044-04,
A812302,
J-011323,
J-520433,
3-(N-methyl-2(R)-pyrrolidinyl methyl)-5-[2-(phenyl sulfonyl)ethyl]-1H-indole hydrobromide,
3-(N-Methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethly)-1H-indole hydrobromide,
3-(N-Methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole hydrobromide,
3-(N-methyl-2(R)-pyrrolidinylmethyl)-5-[2-(phenyl sulfonyl)ethyl]-1H-indole hydrobromide,
3-{[1-Methylpyrrolidin-2(R)-yl]methyl}-5-(2-phenylsulphonylethyl)-1H-indole hydrobromide,
(r)-3-[(1-methyl-2-pyrrolidinyl) methyl]-5-[2-(phenylsulfonyl) ethyl]-1h-indole monohydrobromide,
(R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole Hydrobromide,
1H-Indole, 3-[[(2R)-1-methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-, hydrobromide (1:1),
3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole hydrobromide,
5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methyl-2-pyrrolidinyl]methyl]-1H-indole hydrobromide,
5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole hydrobromide,
5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole;hydrobromide,
Eletriptan hydrobromide; 1H-Indole,3-[(1-methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-,monohydrobromide, (R)-,
Eletriptan,
Relpax,
C22H26N2O2S.BrH,
CID656631,
C22-H26-N2-O2-S.Br-H,
CS-O-01418,
UK-116044,
B2237,
UK-116044-04,
143322-58-1,
(S)-3-((1-Methylpyrrolidin-2-yl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole,
Eletriptan hydrobromide, 99%, a selective 5-HT1B/1D receptor agonist - 1G 1g,
3-(((2R)-1-Methyl-2-pyrrolidinyl))methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide,